Patents Examined by Lei Yao
  • Methods and kits for the prognosis and treatment of prostate cancer
    Patent number: 10221460
    Abstract: Provided herein are methods for the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient. In particular, gene expression levels of GCOM1, MEX3D, TRPM4, ATPAF1, PTRF, GLYATL1, FLNA, OBSCN, STRA13, WHSC1, ARFGAP3, KDM2A, FAM83H, CLDN7, CNOT6, and B3GNT9 are measured. Kits containing means for the measurement of gene expression as described herein and methods for treatment of prostate cancer are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: March 5, 2019
    Assignee: Washington State University
    Inventors: Grant D. Trobridge, Arun Kumar Nalla
  • Bcl-2-like protein 11 SRM/MRM assay
    Patent number: 10215761
    Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: February 26, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10214577
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: February 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • SRM/MRM assay for the ephrin type-A receptor 2 protein
    Patent number: 10202635
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10202437
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: February 12, 2019
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Modulation of tumor immunity
    Patent number: 10188729
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Bi-specific antibodies and uses thereof
    Patent number: 10188742
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: January 29, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10189886
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: January 29, 2019
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor receptor (VEGFR)
    Patent number: 10191058
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 29, 2019
    Assignee: CELLTREND GMBH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Anti-human 4-1BB antibodies and uses thereof
    Patent number: 10174122
    Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: January 8, 2019
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
  • Methods and compositions for treating solid tumors and enhancing tumor vaccines
    Patent number: 10174120
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: January 8, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J Buckanovich, George Coukos, Andrea Facciabene
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10167331
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: January 1, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Method for prophylaxis and/or treatment of ErbB2 positive cancers
    Patent number: 10155028
    Abstract: Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: December 18, 2018
    Assignee: Health Research, Inc.
    Inventors: Yuesheng Zhang, Lu Yang, Yun Li
  • Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
    Patent number: 10130693
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: November 20, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Methods and compositions for detecting endometrial or ovarian cancer
    Patent number: 10126311
    Abstract: Some embodiments of the present invention relate to methods and compositions for assessing the absence, presence, progression, or stage of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 13, 2018
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannell
  • Methods and compounds for reducing threonyl-tRNA synthetase activity
    Patent number: 10087435
    Abstract: The invention includes, in part, methods and compounds for treating diseases and conditions characterized by elevated threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is elevated as compared to normal. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess a treatment for a disease or condition characterized by elevated TARS activity.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 2, 2018
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher Francklyn, Karen M. Lounsbury, Jason Botten
  • Molecular marker for cancer stem cell
    Patent number: 10080776
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 25, 2018
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Esophageal cancer marker and use thereof
    Patent number: 10077316
    Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: September 18, 2018
    Assignee: National University Corporation, Kochi University
    Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
  • Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
    Patent number: 10059775
    Abstract: The present invention is directed to antibodies binding to MUC1-C/extracellular domain (MUC1-C/ECD) and methods of using such antibodies to treat cancers that express the MUC1 antigen.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: August 28, 2018
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Methods and compositions for assaying blood levels of legumain
    Patent number: 10048267
    Abstract: In one aspect, a homogenous assay method for determination of blood levels of legumain molecules (an asparaginyl endopeptidase) is disclosed. In one aspect, the assay utilizes specific sizes of nanoparticles that are coated with antibody or antibodies specifically towards legumain molecule or its fragment(s). In one aspect, the assay is designed in a homogenous manner with a dynamic range from 0.2 to 160 ng/mL. In another aspect, disclosed herein is a kit for assaying blood levels of legumain comprising two parts of reagents (R1 and R2), which kit is adaptable to be used on clinical chemistry analyzers. In one aspect, the cut-off values for differentiating normal from high risk of cancers such as breast cancer, colorectal cancer and stomach cancer are 18±3 ng/mL.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: August 14, 2018
    Assignee: NINGBO ZIYUAN MEDICAL DEVICES INC.
    Inventors: Xiaohong Yu, Fang Guo